Introduction
Endometriosis (EM) and inflammatory bowel disease (IBD) are characterized by chronic inflammation and immune dysregulation, with overlapping presentations that can delay diagnosis of IBD. Epidemiological studies have demonstrated a positive association between EM and IBD, with a large Danish cohort study reporting a 50% increased risk of IBD in women with EM. However, this relationship remains poorly characterized in the US.
Aims & Methods
We performed a retrospective cohort study using the TriNetX database to evaluate IBD risk in female patients with EM vs controls in the US population. Patients with EM were identified using ≥2 ICD-10-CM codes between 2010-2020, and individuals with pre-existing IBD were excluded. Primary aim was to assess the risk of IBD, including ulcerative colitis (UC) and Crohn's disease (CD), in the EM cohort compared to patients without EM (control cohort). Sensitivity analyses incorporated 6- and 12-month washout periods and required IBD-related medication prescriptions. Subgroup analyses were conducted based on oral contraceptive (OCP) use, EM surgery, age, race/ethnicity, and comorbid autoimmune (AI) diseases. One-to-one propensity score matching (PSM) was performed balance the following covariates between the endometriosis and control cohort: age at index, race/ethnicity, diabetes mellitus, nicotine dependence, co-morbid autoimmune diseases, long-term non-steroidal anti-inflammatory use, antibiotic use, and BMI. Adjusted odds ratio (aOR) with 95% confidence intervals (CI) were calculated.
Results
The EM cohort included 117,501 patients (mean age 37.2 ± 10.6; BMI 29 ± 7.5 kg/m²; 69.9% White; 42.5% OCP use), matched to 117,501 controls. After median follow-up of 6.6 years, 1,327 (1.12%) patients developed IBD vs 748 (0.63%) controls. The EM cohort had significantly increased odds of IBD (aOR 1.78, 95% CI 1.62-1.95; p<0.0001), including UC (aOR 1.55, 95% CI 1.38-1.74; p<0.0001) and CD (aOR 2.17, 95% CI 1.90-2.49; p<0.0001). This remained significant after 6-month (aOR 1.81, 95% CI 1.65-2.00) and 12-month (aOR 2.05, 95% CI 1.84-2.27) washout periods. Both patients with and without OCP use had increased odds of IBD. Increased risk persisted across age groups (18-50 years: aOR 2.16 [1.93-2.41]; >50 years: aOR 2.94 [2.37-3.65]), White (aOR 1.83 [1.64-2.03]) and Black race (aOR 2.91 [2.14-3.95]), and Hispanic ethnicity (1.63 [1.17-2.26]). Patients with AI comorbidity had notably higher odds (aOR 3.12, [2.43-4.01]).
Table: Risk of IBD in the endometriosis cohort compared to the control. Sensitivity analysis conducted based on extended washout periods, oral contraceptive (OCP) use, ovarian endometriosis, infertility and endometriosis surgery.
| Endometriosis cohort | Control cohort | aOR (95% CI) |
Overall
| 1,327 (1.12%)
| 748 (0.63%)
| 1.78 (1.62-1.95)
|
6-month washout
| 1,199 (1.0%)
| 662 (0.55%)
| 1.81 (1.65-2.00)
|
12-month washout
| 1,086 (0.90%)
| 532 (0.44%)
| 2.05 (1.84-2.27)
|
OCP use
| 606 (1.21%)
| 293 (0.58%)
| 2.08 (1.80-2.39)
|
IUD use
| 130 (1.19%)
| 66 (0.60%)
| 1.98 (1.47-2.66)
|
Ovarian endometriosis
| 255 (1.01%)
| 165 (0.65%)
| 1.55 (1.27-1.88)
|
Endometriosis with infertility
| 106 (0.94%)
| 64 (0.57%)
| 1.66 (1.21-2.27)
|
Endometriosis surgery
| 489 (1.12%)
| 299 (0.68%)
| 1.64 (1.42-1.89)
|
IBD plus medication
| 431 (0.35%)
| 9350 (0.17%)
| 2.06 (1.87-2.27)
|
Conclusion
EM patients had significantly increased risk of developing IBD, including both UC and CD. This association persisted across multiple sensitivity analyses, age groups, and racial/ethnic subgroups, with notably higher risk in those with AI comorbidity, suggesting higher inflammatory burden in this population.
Disclosure
Raina Shivashankar: Speaker Bureau: Abbvie, BMS; Grant Support: Janssen
Gursimran Kochhar: Speaker: Lilly Pharma. Advisor Board: GIE Medical, Lilly Pharma, CorEvitas Research foundation, Pharmacocosmos. Consultant: Pentax endoscopy, Olympus endoscopy, Boston Scientific endoscopy, Exact Sciences. Stock Options: Digbi Health
Francis Farraye: Consulting fee – Astellas, Avalo Therapeutics, Bausch, Biocon, Braintree Labs, GI Reviewers, GSK, IBD Educational Group, Iterative Health, Janssen, Metaphore Biotechnologies, Pharmacosmos, Pfizer, Sandoz Immunology. DSMB – Eli Lilly, MoonLake
Aakash Desai: Consultant for Takeda. Speaker for Janssen.